Dengue vaccines: preparing to roll back dengue.
Dengue is an emerging viral pathogen of growing global importance, infecting up to 100 million people annually. Although there have been many efforts over the last six decades to produce a vaccine to combat this infection, few have been able to meet the challenges posed by the unusual interplay between this virus and its human host. However, recent progress in molecular-based vaccine strategies, as well as a renewed commitment by the World Health Organisation to co-ordinate global efforts on vaccine development, finally provides hope that control of this serious disease may be at hand.
Jacobs
Michael
M
Centre for Hepatology, Department of Medicine, Royal Free & University College Medical School, Rowland Hill Street, London, NW3 2PF, UK. michael.jacobs@rfc.ucl.ac.uk
Young
Paul
P
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology / Q000502:physiology; D003715:Dengue / Q000276:immunology* / Q000517:prevention & control*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D012703:Serotyping; D014613:Vaccines, Attenuated / Q000276:immunology; D019444:Vaccines, DNA / Q000276:immunology; D014765:Viral Vaccines / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014765:Viral Vaccines